Harpoon Therapeutics Abstract for HPN217 Accepted for Presentation at the 65th American Society of Hematology (ASH) Annual Meeting and Exposition
02 Novembro 2023 - 10:15AM
Harpoon Therapeutics, Inc. (Nasdaq: HARP), a clinical-stage
immunotherapy company developing novel T cell engagers, today
announced abstract acceptance and upcoming oral presentation of the
results from the completed dose escalation portion of the Phase 1
study of HPN217 in patients with relapsed/refractory multiple
myeloma. The oral presentation will take place at the upcoming 65th
American Society of Hematology (ASH) Annual Meeting and Exposition
being held December 9-12, 2023, in San Diego.
Details of the ASH presentation are as follows:
Title: Results from the Completed Dose
Escalation Portion of the Phase 1 Study of HPN217, a Half-Life
Extended Tri-Specific T Cell Activating Construct (TriTAC®)
Targeting B Cell Maturation Antigen (BCMA) for Relapsed/Refractory
Multiple Myeloma (MM)Publication
Number: 1012Presenter: Sumit Madan,
M.D., Banner MD Anderson Cancer CenterSession
Name: 653. Multiple Myeloma: Prospective Therapeutics
Trials: Relapsed and Refractory Myeloma Session
Room: Manchester Grand Hyatt San Diego, Seaport Ballroom
ABCDDate: Monday, December 11,
2023Time: Viewing – 4:30 to 6:00 p.m. PT / 7:30 to
9:00 p.m. ET, Presentation – 5:15 p.m. PT / 8:15 p.m. ET
The presentation will also be available on Harpoon’s website
following the session.
For more details about the ASH Annual Meeting, please
visit:https://www.hematology.org/meetings/annual-meeting
About Harpoon Therapeutics Harpoon
Therapeutics is a clinical-stage immunotherapy company
developing a novel class of T cell engagers that harness the power
of the body’s immune system to treat patients suffering from cancer
and other diseases. T cell engagers are engineered proteins that
direct a patient’s own T cells to kill target cells that express
specific proteins, or antigens, carried by the target cells. Using
its proprietary Tri-specific T cell Activating Construct (TriTAC®)
platform, Harpoon is developing a pipeline of novel
TriTACs initially focused on the treatment of solid tumors and
hematologic malignancies. Harpoon has also developed a proprietary
ProTriTAC™ platform, which applies a prodrug concept to its
TriTAC platform to create a therapeutic T cell engager that
remains inactive until it reaches the tumor. Harpoon’s third
proprietary technology platform, extended release TriTAC-XR, is
designed to mitigate cytokine release syndrome. For additional
information about Harpoon Therapeutics, please visit
www.harpoontx.com.
Forward-Looking Statements This press release
contains forward-looking statements within the meaning of the
Private Securities Litigation Reform Act of 1995. Words such as
“continue,” “look forward,” “move towards,” “potential,” “suggest,”
“will,” and similar expressions (as well as other words or
expressions referencing future events, conditions or circumstances)
are intended to identify forward-looking statements. These
forward-looking statements are based on Harpoon Therapeutics’
expectations and assumptions as of the date of this press release.
Each of these forward-looking statements involves risks and
uncertainties that could cause Harpoon Therapeutics’ clinical
development programs, future results, or performance to differ
significantly from those expressed or implied by the
forward-looking statements. Forward-looking statements contained in
this press release include, but are not limited to, statements
relating to Harpoon’s data presentation plans and other statements
that are not historical fact. Many factors may cause differences
between current expectations and actual results, including
unexpected safety or efficacy data observed during clinical
studies, preliminary data and trends may not be predictive of
future data or results, may not demonstrate safety or efficacy
or lead to regulatory approval by the FDA or other regulatory
agencies, clinical trial site activation or enrollment rates that
are lower than expected, changes in expected or existing
competition, changes in the regulatory environment, the
uncertainties and timing of the regulatory approval process, the
timing and results of unexpected litigation or other disputes, and
the sufficiency of Harpoon Therapeutics’ cash resources. These and
other factors that may cause Harpoon Therapeutics’ actual results
to differ from those expressed or implied in the forward-looking
statements in this press release are discussed in Harpoon
Therapeutics’ filings with the U.S. Securities and Exchange
Commission, including under “Risk Factors” in Harpoon Therapeutics’
quarterly report on Form 10-Q for the quarter ended June 30,
2023, and future filings by Harpoon Therapeutics. Except
as required by law, Harpoon Therapeutics assumes no
obligation to update any forward-looking statements contained
herein to reflect any change in expectations, even as new
information becomes available.
Contact:Ana KaporHarpoon
Therapeuticsinvestors@harpoontx.com
Harpoon Therapeutics (NASDAQ:HARP)
Gráfico Histórico do Ativo
De Set 2024 até Out 2024
Harpoon Therapeutics (NASDAQ:HARP)
Gráfico Histórico do Ativo
De Out 2023 até Out 2024